RESEARCHER PROFILE

Vanessa Roldán

← Back to Universidad de Murcia

V

Universidad de Murcia

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsAcute Ischemic Stroke ManagementBlood properties and coagulation

Vanessa Roldán works in Atrial Fibrillation Management and Outcomes, Venous Thromboembolism Diagnosis and Management, Blood Coagulation and Thrombosis Mechanisms, Acute Ischemic Stroke Management, Blood properties and coagulation. Recorded institutional associations include Instituto Murciano de Investigación Biosanitaria, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia.

395Publications
11,712Citations
50H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

    2018 · 2,125 citations

  2. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

    2021 · 1,126 citations

  3. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

    2018 · 247 citations

  4. Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting

    2005 · 214 citations

  5. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)

    2015 · 197 citations

  6. Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a “Real-World” Population With Atrial Fibrillation Receiving Anticoagulant Therapy

    2012 · 193 citations

  7. The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation

    2013 · 190 citations

  8. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation

    2013 · 187 citations

  9. Soluble E-selectin in cardiovascular disease and its risk factors

    2003 · 182 citations

  10. Manejo perioperatorio y periprocedimiento del tratamiento antitrombótico: documento de consenso de SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT y AEU

    2018 · 153 citations

  11. Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation

    2012 · 149 citations

  12. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation

    2003 · 135 citations

  13. Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients

    2011 · 131 citations

  14. SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation

    2014 · 124 citations

  15. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome

    2011 · 120 citations

  16. Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding)

    2013 · 118 citations

  17. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología

    2020 · 115 citations

  18. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

    2022 · 113 citations

  19. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?

    2013 · 112 citations

  20. High sensitivity cardiac troponin T and interleukin‐6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation

    2012 · 106 citations

  21. Pharmacogenetics in Cardiovascular Antithrombotic Therapy

    2009 · 106 citations

  22. A multimarker risk stratification approach to non‐ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro‐BNP and fibrin D‐dimer levels

    2007 · 105 citations

  23. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis

    2007 · 105 citations

  24. Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?

    2003 · 99 citations

  25. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis

    2008 · 98 citations

← Return to the university profile